8-K: Prestige Consumer Healthcare Reports Record Q3 Results, Raises Full-Year Earnings Outlook

Prestige Consumer Healthcare Inc. announced record third-quarter results with revenue up 2.7% and raised its full-year earnings outlook, driven by strong international performance and improved Clear Eyes revenues.

Summary

• Prestige Consumer Healthcare Inc. reported its financial results for the third quarter and first nine months ended December 31, 2024.
• Third-quarter revenue reached a record $290.3 million, a 2.7% increase from $282.7 million in the prior year.
• Diluted earnings per share (EPS) for the third quarter increased by approximately 15% to $1.22, compared to $1.06 in the prior year.
• The company reduced its leverage ratio to 2.5x, driven by strong profitability and cash flow.
• For the first nine months of fiscal 2025, revenue totaled $841.2 million, a slight decrease of 0.8% compared to $848.4 million in the same period last year.
• Diluted EPS for the first nine months was $3.28, compared to $3.19 in the prior year.
• The company is raising its full-year fiscal 2025 earnings outlook to approximately $4.50 adjusted diluted EPS.
• Free cash flow for the first nine months was $184.9 million, an increase compared to $175.6 million in the prior year.
• The company repurchased approximately 0.6 million shares for a total investment of approximately $40.2 million in the first nine months of fiscal 2025.
• Net debt as of December 31, 2024, was approximately $0.9 billion.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record revenue, increased EPS, and a raised full-year earnings outlook. The company's strong financial performance and strategic capital allocation contribute to a favorable sentiment.

Positives

• Record quarterly revenue of $290.3 million was achieved in Q3 FY25.
• Diluted EPS increased by 15% to $1.22 in Q3 FY25.
• The company's leverage ratio improved to 2.5x.
• The full-year earnings outlook has been raised to approximately $4.50 adjusted diluted EPS.
• Free cash flow increased to $184.9 million for the first nine months of fiscal 2025.
• The International OTC Healthcare segment experienced strong growth, particularly in Australia.
• The company reduced its variable debt balance to zero.
• The company repurchased approximately 600,000 shares YTD for $40 million.

Negatives

• Revenue for the first nine months of fiscal 2025 decreased by 0.8% compared to the prior year.
• The North American OTC Healthcare segment saw lower sales in the Cough & Cold, Women's Health, and Oral Care categories.
• The company experienced a limited ability to fully supply demand for Clear Eyes during the first nine months.

Risks

• The company faces risks related to economic and business conditions, including labor shortages, inflation, and geopolitical instability.
• Consumer trends and competitive pressures could impact the company's performance.
• Fluctuations in foreign exchange rates and evolving U.S. and international tariffs pose risks.
• The ability of manufacturing operations and third-party manufacturers to meet demand and avoid inflationary cost increases is a concern.

Future Outlook

The company expects revenues of $1,128 to $1,132 million for fiscal year 2025, with organic growth of approximately 1%. Adjusted Diluted EPS is projected to be approximately $4.50, and free cash flow is expected to be $240 million or more.

Management Comments

• Ron Lombardi, Chief Executive Officer, stated that the company is pleased with the strong third-quarter results, which delivered record quarterly sales and earnings per share.
• Ron Lombardi noted that continued robust free cash flow enabled the company to pay off all remaining variable debt, allowing for further capital allocation opportunities to drive shareholder value as they approach fiscal 2026.
• Ron Lombardi stated that the company's sales performance year-to-date sets them up well to achieve their fiscal 2025 outlook and for approximately 1% organic revenue growth.
• Ron Lombardi concluded that the company's proven business strategy continues to deliver strong financial performance and leaves them well-positioned to deliver additional shareholder value through their anticipated robust long-term free cash flow generation.

Industry Context

Prestige Consumer Healthcare operates in the consumer healthcare products industry, competing with other companies that offer over-the-counter (OTC) medications and personal care products. The company's focus on brand-building and strategic capital allocation is consistent with industry trends aimed at maximizing shareholder value.

Comparison to Industry Standards

• Comparing Prestige Consumer Healthcare's leverage ratio of 2.5x to competitors like Church & Dwight (CHD) and Reckitt Benckiser (RBGLY) shows a similar approach to financial management.
• The company's focus on free cash flow generation aligns with industry best practices, as companies like Johnson & Johnson (JNJ) and Procter & Gamble (PG) prioritize cash flow for dividends, share repurchases, and acquisitions.
• Prestige's growth in the International OTC segment mirrors the broader industry trend of expanding into international markets to capture growth opportunities, similar to Sanofi (SNY) and Bayer (BAYRY).

Stakeholder Impact

• Shareholders will benefit from increased earnings per share and potential share repurchases.
• Employees may experience increased job security due to the company's strong financial performance.
• Customers will continue to have access to the company's diverse portfolio of healthcare products.
• Creditors will have increased confidence in the company's ability to meet its debt obligations.

Next Steps

• The company will continue to focus on brand-building and strategic capital allocation.
• The company will host a conference call to review its third quarter fiscal 2025 results on February 6, 2025.
• The company will continue to evaluate M&A and share buybacks as optimal capital allocation levers.

Key Dates

Keywords

Prestige Consumer Healthcare, financial results, earnings, revenue, OTC healthcare, free cash flow, EPS, debt reduction, share repurchase, international growth